Physician profile
Jennyffer Miller
NPI 1891137709
$2,715.32
in general payments reported to CMS, 2019-2025
14 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Addiction Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.72 · 2020: $76.12 · 2021: $216 · 2022: $169 · 2023: $1,245 · 2024: $501 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,212.21 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $566.85 | 2022-2024 | |
| Alkermes, INC. | $489.95 | 2020-2025 | Vivitrol, Vivitrol |
| Neurocrine Biosciences, INC. | $347.57 | 2022-2025 | Ingrezza |
| Braeburn INC. | $295.89 | 2023-2025 | Brixadi |
| Indivior INC. | $275.25 | 2019-2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $182.96 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $143.29 | 2023-2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.97 | 2023 | |
| Uswm, LLC | $94.60 | 2021-2023 | Lucemyra |
| Otsuka America Pharmaceutical, INC. | $84.79 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Masimo Corporation | $37.20 | 2023 | Bridge |
| Luye Pharma (USA) Ltd. | $28.99 | 2025 | Erzofri Extended-Release |
| Janssen Pharmaceuticals, INC | $23.20 | 2024 | Spravato |
| Gilead Sciences, INC. | $19.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennyffer Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.